Skip to main contentSkip to navigationSkip to search
HNSA (, %) SEK
Hansa Biopharma logotype

Hansa Medical redeems convertible loan – positive earnings effect of SEK 15.1 M

Regulatory information
Hansa Medical has entered into an agreement covering the repayment of the convertible loan granted to the company by Biolin AB (publ) in connection with Hansa Medical’s spinoff from Biolin in 2007. Hansa Medical and Biolin have agreed that the convertible loan will be redeemed through a cash payment totaling SEK 7.0 M. The transaction entailed a positive effect of SEK 15.1 M on earnings before tax in the Hansa Medical Group.

Hansa Medical’s CEO, Emanuel Björne:“The convertible loan constituted a dilution risk for Hansa Medical corresponding to approximately 26 percent. This redemption will make it easier to value Hansa Medical and should contribute to generating increased interest in the company.”In conjunction with the spinoff, Hansa Medical (publ) acquired all shares in Hansa Medical Utvecklings AB from Biolin. Hansa Medical paid for the transfer of shares by way of an agreement regulating a convertible loan from Biolin amounting to SEK 33.6 M, corresponding to a discounted present value of SEK 22.1 M in the consolidated balance sheet.The Hansa Medical share has been traded on First North under the ticker symbol HMED since October 17, 2007, and the company’s certified adviser is Kaupthing Bank.For more information, please contact:Emanuel Björne, CEOMobile: +46 707 17 54 77E-mail: emanuel.bjorne@hansamedical.com Bo Håkansson, Chairman of the BoardMobile: +46 705 98 57 22E-mail: bo.hakansson@farstorp.com

Downloads